Portfolio Holdings Detail for ISIN IE00BF20LF40
| Stock Name / Fund | iShares MSCI Europe Mid Cap UCITS ETF EUR (Acc) |
| Issuer | Blackrock |
| ETF Ticker | EUMD(EUR) LSE |
| ETF Ticker | EUMD.LS(EUR) CXE |
| ETF Ticker | EUMD.L(GBP) LSE |
Holdings detail for EBS
| Stock Name | Emergent Biosolutions Inc |
| Ticker | EBS(USD) NYSE |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US29089Q1058 |
| LEI | 549300YW6TUOX8BE5103 |
Show aggregate EBS holdings
News associated with EBS
- Emergent BioSolutions Wins $17 Million BARDA Contract To Supply Tembexa Oral Suspension
- (RTTNews) - Emergent BioSolutions Inc. (EBS) on Monday announced a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the ASPR within the U.S. Department of Health and Human Services (HHS), to supply Tembexa oral sus - 2025-09-15 11:47:25
- HC Wainwright Reaffirms Buy Rating for Emergent Biosolutions (NYSE:EBS)
- Emergent Biosolutions (NYSE:EBS – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $15.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 97.24% from the stock’s current price. Separately, Wall […] - 2025-09-05 05:55:02
- Y Intercept Hong Kong Ltd Takes Position in Emergent Biosolutions Inc. (NYSE:EBS)
- Y Intercept Hong Kong Ltd purchased a new stake in shares of Emergent Biosolutions Inc. (NYSE:EBS – Free Report) during the first quarter, Holdings Channel reports. The fund purchased 95,026 shares of the biopharmaceutical company’s stock, valued at approximately $462,000. A number of other hedge funds have also recently made changes to their positions in […] - 2025-07-29 06:56:53
- Emergent Biosolutions (NYSE:EBS) vs. Celularity (NASDAQ:CELU) Critical Review
- Emergent Biosolutions (NYSE:EBS – Get Free Report) and Celularity (NASDAQ:CELU – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, analyst recommendations, earnings, risk and institutional ownership. Valuation and Earnings This table compares Emergent Biosolutions […] - 2025-07-29 05:11:00
- New York State Common Retirement Fund Grows Holdings in Emergent Biosolutions Inc. (NYSE:EBS)
- New York State Common Retirement Fund grew its stake in shares of Emergent Biosolutions Inc. (NYSE:EBS – Free Report) by 22.4% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 375,034 shares of the biopharmaceutical company’s stock after acquiring an additional 68,748 shares during the period. New […] - 2025-07-24 05:44:47
- Lazard Asset Management LLC Has $528,000 Stock Holdings in Emergent BioSolutions Inc. (NYSE:EBS)
- Lazard Asset Management LLC raised its stake in Emergent BioSolutions Inc. (NYSE:EBS – Free Report) by 541.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 55,303 shares of the biopharmaceutical company’s stock after purchasing an additional 46,676 shares during the […] - 2025-05-22 07:30:44
- Gotham Asset Management LLC Takes $200,000 Position in Emergent BioSolutions Inc. (NYSE:EBS)
- Gotham Asset Management LLC acquired a new stake in Emergent BioSolutions Inc. (NYSE:EBS – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 20,908 shares of the biopharmaceutical company’s stock, valued at approximately $200,000. Other hedge funds also recently made changes to […] - 2025-05-22 06:20:49
- Emergent BioSolutions Inc. (NYSE:EBS) Stock Holdings Lessened by D. E. Shaw & Co. Inc.
- D. E. Shaw & Co. Inc. trimmed its stake in Emergent BioSolutions Inc. (NYSE:EBS – Free Report) by 50.3% in the fourth quarter, Holdings Channel.com reports. The firm owned 383,043 shares of the biopharmaceutical company’s stock after selling 388,095 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Emergent BioSolutions were worth […] - 2025-05-19 07:34:50
- Balyasny Asset Management L.P. Purchases New Shares in Emergent BioSolutions Inc. (NYSE:EBS)
- Balyasny Asset Management L.P. acquired a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 13,286 shares of the biopharmaceutical company’s stock, valued at approximately $127,000. A number of other institutional investors also recently […] - 2025-05-19 05:48:50
- Cetera Investment Advisers Sells 107,236 Shares of Emergent BioSolutions Inc. (NYSE:EBS)
- Cetera Investment Advisers lessened its position in Emergent BioSolutions Inc. (NYSE:EBS – Free Report) by 27.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 277,247 shares of the biopharmaceutical company’s stock after selling 107,236 shares during the period. Cetera Investment Advisers […] - 2025-05-18 07:01:04
- Hsbc Holdings PLC Lowers Stock Holdings in Emergent BioSolutions Inc. (NYSE:EBS)
- Hsbc Holdings PLC reduced its position in Emergent BioSolutions Inc. (NYSE:EBS – Free Report) by 47.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 18,727 shares of the biopharmaceutical company’s stock after selling 16,944 shares during the quarter. Hsbc Holdings PLC’s holdings in Emergent BioSolutions were worth $178,000 at the end of the […] - 2025-05-12 06:06:52
- Tower Research Capital LLC TRC Purchases 16,345 Shares of Emergent BioSolutions Inc. (NYSE:EBS)
- Tower Research Capital LLC TRC lifted its position in shares of Emergent BioSolutions Inc. (NYSE:EBS – Free Report) by 7,075.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,576 shares of the biopharmaceutical company’s stock after purchasing an additional 16,345 shares […] - 2025-05-07 06:32:58
- Federated Hermes Inc. Acquires 6,058 Shares of Emergent BioSolutions Inc. (NYSE:EBS)
- Federated Hermes Inc. increased its holdings in Emergent BioSolutions Inc. (NYSE:EBS – Free Report) by 2.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 277,810 shares of the biopharmaceutical company’s stock after purchasing an additional 6,058 shares during the period. Federated Hermes Inc.’s holdings in […] - 2025-04-14 06:14:59
- Emergent BioSolutions (NYSE:EBS) Board Announces Stock Repurchase Plan
- Emergent BioSolutions (NYSE:EBS – Get Free Report) declared that its board has approved a share repurchase plan on Monday, March 31st, RTT News reports. The company plans to buyback $50.00 million in shares. This buyback authorization permits the biopharmaceutical company to purchase up to 19% of its stock through open market purchases. Stock buyback plans […] - 2025-04-02 03:06:43
- HC Wainwright Reaffirms Buy Rating for Emergent BioSolutions (NYSE:EBS)
- Emergent BioSolutions (NYSE:EBS – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $15.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 158.84% from the stock’s previous close. […] - 2025-03-06 07:57:28
- Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript
- Image source: The Motley Fool. - 2025-03-04 05:45:13
- Emergent BioSolutions Inc. (NYSE:EBS) Holdings Boosted by New York State Common Retirement Fund
- New York State Common Retirement Fund boosted its position in shares of Emergent BioSolutions Inc. (NYSE:EBS – Free Report) by 41.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 306,286 shares of the biopharmaceutical company’s stock after purchasing an additional 90,113 shares during […] - 2025-03-02 08:16:49
- Emergent BioSolutions (NYSE:EBS) Raised to Buy at StockNews.com
- Emergent BioSolutions (NYSE:EBS – Get Free Report) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Monday. Other analysts have also recently issued reports about the stock. HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of Emergent […] - 2025-02-19 04:18:51
- Emergent BioSolutions (NYSE:EBS) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened
- Emergent BioSolutions Inc. (NYSE:EBS – Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $9.25 and traded as high as $10.49. Emergent BioSolutions shares last traded at $10.10, with a volume of 665,056 shares. Analyst Upgrades and Downgrades Several research firms […] - 2025-02-11 06:26:59
- Emergent BioSolutions (NYSE:EBS) and MusclePharm (OTCMKTS:MSLP) Head-To-Head Contrast
- MusclePharm (OTCMKTS:MSLP – Get Free Report) and Emergent BioSolutions (NYSE:EBS – Get Free Report) are both small-cap consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk. Institutional and Insider Ownership 15.5% of MusclePharm […] - 2025-02-06 05:01:05
iShares MSCI Europe Mid Cap UCITS ETF EUR (Acc) EBS holdings
| Date | Number of EBS Shares Held | Base Market Value of EBS Shares | Local Market Value of EBS Shares | Change in EBS Shares Held | Change in EBS Base Value | Current Price per EBS Share Held | Previous Price per EBS Share Held |
|---|
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projectionThe likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of EBS
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 239,928 | 912 | 406,109 | 59.1% |
| 2025-09-18 | 218,064 | 367 | 332,040 | 65.7% |
| 2025-09-17 | 156,391 | 2 | 327,454 | 47.8% |
| 2025-09-16 | 162,547 | 8 | 216,038 | 75.2% |
| 2025-09-15 | 201,738 | 1,500 | 287,342 | 70.2% |
| 2025-09-12 | 189,025 | 2,565 | 282,906 | 66.8% |
| 2025-09-11 | 184,176 | 50 | 312,961 | 58.8% |
| 2025-09-10 | 215,243 | 4,810 | 423,137 | 50.9% |
| 2025-09-09 | 329,824 | 3,000 | 544,245 | 60.6% |
| 2025-09-08 | 196,176 | 0 | 310,889 | 63.1% |
| 2025-09-05 | 188,429 | 1,230 | 308,501 | 61.1% |
| 2025-09-04 | 189,291 | 0 | 360,918 | 52.4% |
| 2025-09-03 | 286,513 | 0 | 505,397 | 56.7% |
| 2025-09-02 | 177,832 | 2,357 | 437,211 | 40.7% |
| 2025-08-29 | 226,098 | 5,500 | 380,186 | 59.5% |
| 2025-08-28 | 245,494 | 0 | 490,673 | 50.0% |
| 2025-08-27 | 117,507 | 201 | 201,520 | 58.3% |
| 2025-08-26 | 209,162 | 755 | 324,452 | 64.5% |
| 2025-08-25 | 222,590 | 344 | 338,810 | 65.7% |
| 2025-08-22 | 243,475 | 4,202 | 475,220 | 51.2% |
| 2025-08-21 | 165,547 | 8,144 | 270,233 | 61.3% |
| 2025-08-20 | 214,610 | 88 | 398,084 | 53.9% |
| 2025-08-19 | 192,741 | 1,361 | 338,710 | 56.9% |
| 2025-08-18 | 357,503 | 1,833 | 559,075 | 63.9% |
| 2025-08-15 | 300,770 | 6 | 462,994 | 65.0% |
| 2025-08-14 | 188,782 | 1,411 | 288,938 | 65.3% |
| 2025-08-13 | 308,863 | 20 | 526,485 | 58.7% |
| 2025-08-12 | 548,010 | 1,702 | 850,808 | 64.4% |
| 2025-08-11 | 329,728 | 4,361 | 587,557 | 56.1% |
| 2025-08-08 | 659,329 | 18,229 | 1,360,548 | 48.5% |
| 2025-08-07 | 1,084,348 | 5,677 | 2,641,996 | 41.0% |
| 2025-08-06 | 287,863 | 0 | 368,233 | 78.2% |
| 2025-08-05 | 305,158 | 3,610 | 389,755 | 78.3% |
| 2025-08-04 | 198,008 | 60 | 274,735 | 72.1% |
| 2025-08-01 | 610,474 | 1 | 659,737 | 92.5% |
| 2025-07-31 | 364,590 | 464 | 501,980 | 72.6% |
| 2025-07-30 | 460,788 | 0 | 713,821 | 64.6% |
| 2025-07-29 | 450,827 | 1,666 | 632,359 | 71.3% |
| 2025-07-28 | 276,681 | 105 | 391,161 | 70.7% |
| 2025-07-25 | 166,245 | 198 | 267,023 | 62.3% |
| 2025-07-24 | 154,228 | 151 | 256,882 | 60.0% |
| 2025-07-23 | 232,961 | 552 | 417,653 | 55.8% |
| 2025-07-22 | 269,682 | 757 | 395,869 | 68.1% |
| 2025-07-21 | 176,928 | 0 | 297,374 | 59.5% |
| 2025-07-18 | 133,708 | 534 | 249,976 | 53.5% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy